344 unknown. 344 Phase 2, 135 Phase 1, 30 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 344 | Unknown 344 |
| Phase 1 | 135 | Unknown 135 |
| Phase 3 | 30 | Unknown 30 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Dasatinib Pill, Ketoconazole Pill - Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2024-11-01 | 2022-12-06 |
| Pharmacoscopy-guided Clinical Standard-of-care in r/r AML Pharmacoscopy, Clinical standard-of-care (physician's choice) - AML, Adult | Phase 2 | Unknown | ETH Zurich | 88 | 2024-09-02 | 2025-05-16 |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia DFP-10917, Venetoclax - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Unknown | Delta-Fly Pharma, Inc. | 39 | 2024-06-12 | 2025-09-03 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult DEC3-VEN - Acute Myeloid Leukemia, Adult | Phase 2 / Phase 3 | Unknown | The Second Affiliated Hospital of Kunming Medical University | 40 | 2024-03-01 | 2024-02-29 |
| Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax - Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 34 | 2024-02-29 | 2024-05-30 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 68 | 2023-10-01 | 2023-10-10 |
| Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML Unrelated umbilical cord blood, Venetoclax, Decetabine - Acute Myelocytic Leukemia | Phase 2 | Unknown | Anhui Provincial Hospital | 20 | 2023-10-01 | 2023-10-30 |
| 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia 90-Yttrium-labelled anti-CD66 monoclonal antibody - Leukemia | Phase 2 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 25 | 2023-09-29 | 2023-10-03 |
| Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 20 | 2023-09-10 | 2023-11-01 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia QHRD107 capsule，Venclexta and Azacitidine - Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) | Phase 2 | Unknown | Changzhou Qianhong Bio-pharma Co., Ltd. | 53 | 2023-08-10 | 2024-08-01 |
| A Study of TQB3454 Tablets in Patients With Blood Tumors TQB3454 Tablets - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2023-07-10 | 2024-01-23 |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Smart Immune SAS | 40 | 2023-06-06 | 2023-09-25 |
| RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT RC1012 injection (allo-DNT cells) - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Guangdong Ruishun Biotech Co., Ltd | 72 | 2023-05-04 | 2023-05-19 |
| Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia Anti-CD56 CAR T - Extranodal NK T Cell Lymphoma, NK-Cell Leukemia | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2023-05-01 | 2023-07-12 |
Showing 20 of 344. Sign in to see all of them.
Leukemia, Myeloid, Acute (151) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (87) · Leukemia, Lymphocytic, Chronic, B-Cell (47) · Lymphoma (47) · Myelodysplastic Syndromes (44) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (30) · Recurrence (30) · Lymphoma, Large B-Cell, Diffuse (26) · Lymphoma, Non-Hodgkin (25) · Lymphoma, Follicular (22) · Burkitt Lymphoma (20) · Multiple Myeloma (20) · Lymphoma, Mantle-Cell (19) · Lymphoma, B-Cell (15)
Hemic and Lymphatic Diseases (344) · Neoplasms by Histologic Type (344) · Hematologic Diseases (343) · Neoplasms (340) · Leukemia, Myeloid (189) · Immune System Diseases (163) · Immunoproliferative Disorders (159) · Lymphoproliferative Disorders (159) · Lymphatic Diseases (157) · Leukemia, Lymphoid (138) · Pathologic Processes (121) · Pathological Conditions, Signs and Symptoms (121) · Disease Attributes (115) · Chronic Disease (89)
Cytarabine (46) · Cyclophosphamide (28) · Azacitidine (17) · Decitabine (16) · Methotrexate (15) · fludarabine (15) · venetoclax (15) · Imatinib Mesylate (14) · Busulfan (13) · Dexamethasone (13) · Idarubicin (13) · Vincristine (13) · Dasatinib (12) · Etoposide (11) · Cladribine (10)
The First Affiliated Hospital of Soochow University (12) · Chinese PLA General Hospital (9) · Nanfang Hospital, Southern Medical University (9) · Southwest Hospital, China (7) · Chongqing Precision Biotech Co., Ltd (6) · The University of Hong Kong (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (5) · Shanghai Jiao Tong University School of Medicine (5) · Sun Yat-sen University (5) · Ascentage Pharma Group Inc. (4) · Cooperative Study Group A for Hematology (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (4) · Sheba Medical Center (4)
China (136) · United States (52) · Germany (23) · France (21) · Italy (18) · South Korea (15) · Belgium (10) · United Kingdom (9) · Canada (7) · Hong Kong (7) · Israel (7) · Netherlands (7) · Russia (7) · Spain (7) · Mexico (5)
Cheng Qian, MD, PhD (6) · Cheng Qian, PhD (6) · Sanbin Wang, MD (3) · Xiaowen Tang, Ph.D (3) · Anna Turkina, Professor (2) · Anskar Leung, Professor (2) · Arnon Nagler, MD (2) · David G. Savage, MD (2) · Depei Wu Wu, MD (2) · Depei Wu, MD. PhD (2) · Eucario Leon Rodriguez, M.D. (2) · Fernando Cabanillas, MD (2) · Hawk Kim, M.D., Ph.D. (2) · Hawk Kim, professor (2)
PMID 34515338, PMID 28054442, PMID 35982483, PMID 40195173, PMID 41671463, PMID 11675328, PMID 11756187, PMID 14603333, PMID 15107815, PMID 16105981, PMID 16155013, PMID 16564913, PMID 17317857, PMID 17366834, PMID 18083847, PMID 18172005, PMID 18182574, PMID 18358930, PMID 19242495, PMID 19536906, PMID 20015886, PMID 20371346, PMID 20644121, PMID 20959411, PMID 20965785, PMID 21220611, PMID 21480469, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22086414, PMID 22265847, PMID 22323480, PMID 22331940, PMID 22589701, PMID 22847303, PMID 23140366, PMID 23244073, PMID 23440689, PMID 23704089, PMID 23704092, PMID 23876833, PMID 24166905, PMID 24311149, PMID 24323036, PMID 24475787, PMID 24488560, PMID 24497570, PMID 24641416
2014 (4), 2005 (1), 2009 (1), 2016 (1), 2017 (1), 2018 (1), 2019 (1), K12HL087165 (1), P30CA015704 (1), P30CA016042 (1)